# OnCo record polargo (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/polargo/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "polargo", "NCT04182204" ;
  schema:name "POLARGO"@en ;
  schema:alternateName "Pola-R-GemOx"@en, "POLARGO trial"@en ;
  schema:description "Adding an antibody-drug conjugate to a gentle outpatient chemotherapy pairing added about seven months of life for people with relapsed aggressive lymphoma who could not have a transplant."@en ;
  schema:url <https://onco.cc/trials/polargo/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04182204>, <https://doi.org/10.1200/JCO-25-02849> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "3" ;
  schema:startDate "2020-02-07" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-transplant-role/> ;
  onco:trials <https://onco.cc/trials/polarix/>, <https://onco.cc/trials/starglo/>, <https://onco.cc/trials/sunmo/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/> .